← All trials
NCT06526455
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2024
- Primary completion
- Jun 30, 2029
- Completion date
- Jun 30, 2029
- First posted
- Jul 29, 2024
- Last posted
- Jul 29, 2024
- Enrollment
- 196
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangdong Medical UniversityLead sponsor
- Guangdong Medical UniversitySponsor investigator
- Jinan UniversityCollaborator
- Maoming People's HospitalCollaborator
- Guangzhou Medical UniversityCollaborator
- Yellow River Sanmenxia hospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.